Dosing-Related Economics Arise During FDA Panel’s Arcapta Review

The Pulmonary-Allergy Drugs Advisory Committee’s discussion of Novartis’ Arcapta Neohaler on March 8 briefly veered off in a direction that surely no sponsor wants to see, with panelists debating whether a drug should be dosed less frequently for economic reasons than proposed by the sponsor.